Translation and replication of hepatitis C virus genomic RNA depends on ancient cellular proteins that control mRNA fates

Nicoletta Scheller, Leonardo Mina, Rui Pedro Galão, +6

Proceedings of the National Academy of Sciences

Viral ReplicationGeneticsLsm1-7 ComplexesMolecular BiologyViral Hepatitis +15

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Marta Palafox, Laia Monserrat, Meritxell Bellet, +35

Nature Communications

Germline Mutations in FAN1 Cause Hereditary Colorectal Cancer by Impairing DNA Repair

Núria Seguí, Leonardo Mina, Conxi Lázaro, +29

Gastroenterology

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

José Manuel Pérez-García, Javier Cortés, Manuel Ruíz‐Borrego, +26

The Lancet

Breast OncologyMedicineChemotherapy De-escalationPathologyBreast Cancer +2

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial

Joan Albanell, José Manuel Pérez-García, Miguel Gil‐Gil, +21

Clinical Cancer Research

On the role of FAN1 in Fanconi anemia

Juan Pablo Trujillo‐Quintero, Leonardo Mina, Roser Pujol, +6

Blood

Hepatitis C virus RNA recombination in cell culture

Jochen Reiter, Gemma Pérez‐Vilaró, Nicoletta Scheller, +3

Journal of Hepatology

Viral ReplicationHepatitis CViral HepatitisHepatitisVirology +5

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial

Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, +20

The Oncologist

Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study

Xavier García del Muro, D. Páez López-Bravo, Miler Andrés Cuéllar-Rivas, +11

European Urology Oncology

UrologyGenitourinary CancerMedicineOrpheus StudyPathology +4

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

Marta Palafox, Laia Monserrat, Meritxell Bellet, +35